Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer

被引：9

作者：

Kumai, Tatsuo ^{[1
]}

Mizukoshi, Eishiro ^{[1
]}

Hashiba, Tomomi ^{[2
]}

Nakagawa, Hidetoshi ^{[2
]}

Kitahara, Masaaki ^{[2
]}

Miyashita, Tomoharu ^{[2
]}

Mochizuki, Takafumi ^{[2
]}

Goto, Shigenori ^{[3
]}

Kamigaki, Takashi ^{[3
]}

Takimoto, Rishu ^{[3
]}

Yamashita, Taro ^{[1
]}

Sakai, Yoshio ^{[1
]}

Yamashita, Tatsuya ^{[1
]}

Honda, Masao ^{[1
]}

Tomita, Katsuro ^{[2
]}

Kaneko, Shuichi ^{[1
]}

机构：

[1] Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan

[2] Kanazawa Adv Med Ctr, Kanazawa, Ishikawa, Japan

[3] Juntendo Univ, Sch Med, Dept Next Generat Cell & Immune Therapy, Seta Clin Grp, Tokyo, Japan

来源：

CYTOTHERAPY | 2021年 / 23卷 / 02期

关键词：

adoptive immunotherapy; alpha beta T cell; flow cytometry; immune cell profiling; pancreatic cancer; PHASE-III; GEMCITABINE; THERAPY; SAFETY;

D O I：

10.1016/j.jcyt.2020.08.001

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Background aims: Immunotherapy is effective for many types of cancer, but its benefits in advanced pancreatic cancer, which has a poor prognosis, are not well established. In this study, the authors examined the effects of adoptive T-cell immunotherapy (ATI) on immune cell profiles and prognosis in patients with unresectable advanced pancreatic cancer. Methods: Seventy-seven patients with unresectable advanced pancreatic cancer were treated with six cycles of alpha beta T cells alone or in combination with chemotherapy or chemoradiation. Immune cell profiles in peripheral blood samples obtained before and after treatment were comprehensively evaluated by flow cytometry. Furthermore, associations between changes in immune cell frequencies and prognosis were determined. Results: ATI prolonged survival to 18.7 months compared with previous estimates of 6.2-11.1 months for patients treated with chemotherapy alone. ATI decreased CD3+CD4+CD8-T cell frequency in peripheral blood and increased CD3+CD4-CD8+T cell frequency. An increase in CD3+T cells and CD3+TCR gamma delta-T cells in peripheral blood after treatment was associated with a good prognosis. Conclusions: ATI altered the immune profile in peripheral blood, including CD3+CD4-CD8+T cells, and improved prognosis in pancreatic cancer. (C) 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

引用

页码：137 / 145

页数：9

共 16 条

[1] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[2]

Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2018.2706, 10.1001/jamaoncol.2016.5688]

[3] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[4] Whole blood interferon- levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer [J].

Ishikawa, Takeshi ;

Kokura, Satoshi ;

Sakamoto, Naoyuki ;

Okayama, Tetsuya ;

Endo, Masahiro ;

Tsuchiya, Reiko ;

Okajima, Manabu ;

Matsuyama, Tatsuzo ;

Adachi, Satoko ;

Kamada, Kazuhiro ;

Katada, Kazuhiro ;

Uchiyama, Kazuhiko ;

Handa, Osamu ;

Takagi, Tomohisa ;

Yagi, Nobuaki ;

Ando, Takashi ;

Uno, Kazuko ;

Naito, Yuji ;

Yoshikawa, Toshikazu .

INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (05) :1119-1125

[5] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [J].

Iwai, Y ;

Ishida, M ;

Tanaka, Y ;

Okazaki, T ;

Honjo, T ;

Minato, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12293-12297

[6]

Kamigaki T, 2014, ANTICANCER RES, V34, P4601

[7] Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma [J].

Karakhanova, S. ;

Ryschich, E. ;

Mosl, B. ;

Harig, S. ;

Jaeger, D. ;

Schmidt, J. ;

Hartwig, W. ;

Werner, J. ;

Bazhin, A. V. .

BRITISH JOURNAL OF CANCER, 2015, 112 (06) :1027-1036

[8] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[9] Regulatory T cells in cancer immunotherapy [J].

Nishikawa, Hiroyoshi ;

Sakaguchi, Shimon .

CURRENT OPINION IN IMMUNOLOGY, 2014, 27 :1-7

[10] Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy [J].

Noguchi, Atsutaka ;

Kaneko, Toru ;

Naitoh, Keiko ;

Saito, Masashi ;

Iwai, Kazuro ;

Maekawa, Ryuji ;

Kamigaki, Takashi ;

Goto, Shigenori .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 18 (01) :90-97

← 1 2 →